Subscribe To

Price Alert Latest News Economic Calendar News

CANF / Can-Fite (CANF) Up on Namodenoson Progress in Pancreatic Cancer

Can-Fite's (CANF) shares rise 11.4% as it reveals its plans of submitting an investigational new drug application. The idea is to initiate expansion studies for namodenoson to treat pancreatic carcinoma. Read More

Demo Live Account See Partner Details

Content Topics

Can

Fite

CANF

Namodenoson

Progress

Pancreatic

Cancer

Can fite

canf

Stock

Posted: Jun 14 2023, 13:28

Author Name: Zacks Investment Research

CANF News

By Zacks Investment Research
October 27, 2023

New Strong Buy Stocks for October 27th

MTRX, OPI, CANF, ENLV and RAIL have been added to the Zacks Rank #1 (Strong Buy) List on October 27, 2023.

By Zacks Investment Research
June 14, 2023

Can-Fite (CANF) Up on Namodenoson Progress in Pancreatic Cancer

Can-Fite's (CANF) shares rise 11.4% as it reveals its plans of submitting an investigational new drug application. The idea is to initiate expansion s

By Zacks Investment Research
May 10, 2023

All You Need to Know About Can-Fite Biopharma Ltd (CANF) Rating Upgrade to Buy

Can-Fite Biopharma Ltd (CANF) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2

By MarketBeat
May 2, 2023

Can-Fite BioPharma Spikes on Pancreatic Cancer Inhibition Finding

Can-Fite BioPharma Ltd. NYSEAMERICAN: CANF is an Israel-based biotechnology firm that develops small-molecule therapeutic treatments for cancers, infl

By Benzinga
June 29, 2022

Can-Fite BioPharma Shares Jump After Piclidenoson Data In Psoriasis Trial

Can-Fite BioPharma Ltd (NYSE: CANF) announced topline results from the COMFORT Phase 3 trial of Piclidenoson in more than 400 adults with moderate

By Business Wire
March 28, 2022

Can-Fite to Present at Dermatology Drug Development Summit Europe on April 6, 2022

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite to Present at Dermatology Drug Development Summit Europe on April 6, 2022

By Benzinga
March 8, 2022

Can-Fite BioPharma Flags Delay In Piclidenoson Data Readout From Psoriasis Study

Citing unanticipated delay in the collection of study data, Can-Fite BioPharma Ltd (NYSE: CANF) said that the topline data from its Phase 3 Comfort

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.